Therapeutic uses of somatostatin and its analogues: Current view and potential applications

Rai, Uma; Thrimawithana, Thilini; Valéry, Céline; Young, Simon

doi:10.1016/j.pharmthera.2015.05.007

Cited by 141 publications

(131 citation statements)

References 174 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…(ssts; sst1-5), thereby modulating various downstream pathways (2,3). Synthetic SST analogs (SSAs)-that is, octreotide and/or pasireotide-are used as valuable tools to treat pituitary and neuroendocrine tumors (NETs) (3,4). Of interest, ssts are expressed in PCa tissues and cell lines and are associated with a decreased growth rate and increased cycle arrest (5)(6)(7)(8).…”

mentioning

confidence: 99%

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer

et al. 2017

View full text Add to dashboard Cite

sst5TMD4, a splice variant of the sst5 gene, is overexpressed and associated with aggressiveness in various endocrine-related tumors, but its presence, functional role, and mechanisms of actions in prostate cancer (PCa)-the most common cancer type in males-is completely unexplored. In this study, formalin-fixed, paraffin-embedded prostate pieces from patients with localized PCa, which included tumoral and nontumoral adjacent regions ( = 45), fresh biopsies from patients with high-risk PCa ( = 52), and healthy fresh prostates from cystoprostatectomies ( = 14) were examined. In addition, PCa cell lines and xenograft models were used to determine the presence and functional role of sst5TMD4. Results demonstrated that sst5TMD4 is overexpressed (mRNA/protein) in PCa samples, and this is especially drastic in metastatic and/or high Gleason score tumor samples. Remarkably, sst5TMD4 expression was associated with an altered frequency of 2 single-nucleotide polymorphisms: rs197055 and rs12599155. In addition, PCa cell lines and xenograft models were used to demonstrate that sst5TMD4 overexpression increases cell proliferation and migration in PCa cells and induces larger tumors in nude mice, whereas its silencing decreased proliferation and migration. Remarkably, sst5TMD4 overexpression activated multiple intracellular pathways (ERK/JNK, MYC/MAX, WNT, retinoblastoma), altered oncogenes and tumor suppressor gene expression, and disrupted the normal response to somatostatin analogs in PCa cells. Altogether, we demonstrate that sst5TMD4 is overexpressed in PCa, especially in those patients with a worse prognosis, and plays an important pathophysiologic role in PCa, which suggesting its potential as a biomarker and/or therapeutic target.-Hormaechea-Agulla, D., Jiménez-Vacas, J. M., Gómez-Gómez, E., L.-López, F., Carrasco-Valiente, J., Valero-Rosa, J., Moreno, M. M., Sánchez-Sánchez, R., Ortega-Salas, R., Gracia-Navarro, F., Culler, M. D., Ibáñez-Costa, A., Gahete, M. D., Requena, M. J., Castaño, J. P., Luque, R. M. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.

show abstract

mentioning

confidence: 99%

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The gross effects of somatostatin lead to reduced stress, thereby providing a protective effect on the pancreatic cells. It also has an excellent safety profile with rare adverse reactions …”

Section: Medical Prevention Of Post‐ercp Complicationsmentioning

confidence: 79%

Chinese expert consensus on perioperative medications for endoscopic retrograde cholangiopancreatography (ERCP)

Bai

Wang

et al. 2019

J of Digest Diseases

View full text Add to dashboard Cite

“…The therapeutic relevance of endogenous miniature proteins cannot be overstated. Indeed, many such miniature proteins have been developed as therapeutics to treat cancers (Rai et al, 2015), diabetes (Meah and Juneja, 2015) and, in the case of oxytocin, as a medication to facilitate childbirth (Shyken and Petrie, 1995).…”

Section: Covalent Linkagesmentioning

confidence: 99%

Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents

Holub

2017

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research Miniature proteins are a class of oligopeptide characterized by their short sequence lengths and ability to adopt well-folded, three-dimensional structures. Because of their biomimetic nature and synthetic tractability, miniature proteins have been used to study a range of biochemical processes including fast protein folding, signal transduction, catalysis and molecular transport. Recently, miniature proteins have been gaining traction as potential therapeutic agents because their small size and ability to fold into defined tertiary structures facilitates their development as protein-based drugs. This research overview discusses emerging developments involving the use of miniature proteins as scaffolds to design novel therapeutics for the treatment and study of human disease. Specifically, this review will explore strategies to: (i) stabilize miniature protein tertiary structure; (ii) optimize biomolecular recognition by grafting functional epitopes onto miniature protein scaffolds; and (iii) enhance cytosolic delivery of miniature proteins through the use of cationic motifs that facilitate endosomal escape. These objectives are discussed not only to address challenges in developing effective miniature protein-based drugs, but also to highlight the tremendous potential miniature proteins hold for combating and understanding human disease. Drug Dev Res 78 : 268-282, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Therapeutic uses of somatostatin and its analogues: Current view and potential applications

Cited by 141 publications

References 174 publications

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer

Chinese expert consensus on perioperative medications for endoscopic retrograde cholangiopancreatography (ERCP)

Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents

Contact Info

Product

Resources

About